Clinical Trial News and Research

RSS

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2014.

29 Apr 2014

Penn researchers demonstrate new app to optimize acute stroke care

Stroke researchers from the Perelman School of Medicine at the University of Pennsylvania will unveil a map demonstrating geographic hotspots of increased stroke mortality across the United States, among a series of stroke studies being presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

29 Apr 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Scientists identify first gene linked to childhood-onset familial dilated cardiomyopathy

Scientists at Icahn School of Medicine at Mount Sinai, along with collaborators at institutions in India, Italy, and Japan, have identified the first gene linked to childhood-onset familial dilated cardiomyopathy (DCM), one of the most common heart muscle diseases in children.

29 Apr 2014

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014

Single cell type actively suppressed in several experimental cancer vaccines

Most cancer vaccines have not lived up to their promise in clinical trials. The reason, many researchers suspect, is that the immune cells that would help the body destroy the tumor - even those reactions boosted by cancer vaccines - are actively suppressed.

29 Apr 2014

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Trophos and AFM-Telethon today announce that data from the pivotal clinical trial of Trophos’ lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology annual meeting to be held in Philadelphia, PA, USA, from April 26 to May 3 2014.

29 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.

28 Apr 2014

Skin Cancer Awareness Month and Melanoma Monday: Mount Sinai experts to share vital skin cancer tips

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. In recognition of May's Skin Cancer Awareness Month and Melanoma Monday on May 5th, Mount Sinai Health System experts are arming the public with vital tips on prevention and offering FREE skin cancer screenings.

26 Apr 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

Blend of soy-dairy proteins may prolong muscle building after resistance exercise, says study

A new study published online in the Journal of Applied Physiology shows additional benefits of consuming a blend of soy and dairy proteins after resistance exercise for building muscle mass.

26 Apr 2014

Studies reveal effect of almonds on diet quality, appetite, adiposity and cardiovascular disease risk factors

Six new almond-related research studies will be presented next week in San Diego at the American Society of Nutrition (ASN)'s Scientific Sessions and Annual Meeting, held in conjunction with Experimental Biology 2014 (EB).

26 Apr 2014

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation.

26 Apr 2014

Lilly launches second medical student education program

Eli Lilly and Company announced today the launch of another medical student education program, an internship for aspiring physicians.

26 Apr 2014

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

25 Apr 2014

Aspirin can lower colon cancer risk among people with high levels of specific gene

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene.

25 Apr 2014

TB Alliance advances first-ever TB drug regimen to global Phase 3 clinical trial

Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase 3 clinical trial.

25 Apr 2014

Two sedative drugs effectively treat prolonged seizures in children

The sedative drugs diazepam (Valium) and lorazepam (Ativan) are equally effective in treating the prolonged seizures known as status epilepticus in children, according to a randomized, controlled study by a multi-institution team of researchers with the Pediatric Emergency Care Applied Research Network, including an expert from the Perelman School of Medicine at the University of Pennsylvania.

25 Apr 2014

Clinical Trial News and Research

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Penn researchers demonstrate new app to optimize acute stroke care

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Scientists identify first gene linked to childhood-onset familial dilated cardiomyopathy

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Single cell type actively suppressed in several experimental cancer vaccines

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Skin Cancer Awareness Month and Melanoma Monday: Mount Sinai experts to share vital skin cancer tips

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Blend of soy-dairy proteins may prolong muscle building after resistance exercise, says study

Studies reveal effect of almonds on diet quality, appetite, adiposity and cardiovascular disease risk factors

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Lilly launches second medical student education program

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Aspirin can lower colon cancer risk among people with high levels of specific gene

TB Alliance advances first-ever TB drug regimen to global Phase 3 clinical trial

Two sedative drugs effectively treat prolonged seizures in children

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer